TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the
“Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today
announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the BMO 2018
Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018, at 3:00 p.m. EST at the
Mandarin Oriental Hotel, New York.
The presentation will be broadcast live and available via replay for
30 days on the Company's website, http://ir.redhillbio.com/events. Please access the website at least 15 minutes ahead of the
conference call to register.
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company,
primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of
gastrointestinal diseases and cancer. RedHill commercializes and promotes four gastrointestinal products in the U.S.:
Donnatal® - a prescription oral adjunctive drug used in the treatment of IBS and acute
enterocolitis; Mytesi® - an anti-diarrheal drug indicated for the symptomatic relief
of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; Esomeprazole Strontium
Delayed-Release Capsules 49.3 mg - a prescription proton pump inhibitor indicated for adults for the treatment of
gastroesophageal reflux disease (GERD) and other gastrointestinal conditions, and EnteraGam®
- a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose
stools. RedHill’s key clinical-stage development programs include: (i) TALICIA®
(RHB-105) for the treatment of Helicobacter pylori infection with an ongoing confirmatory Phase
III study and positive results from a first Phase III study; (ii) RHB-104, with positive top-line results from a
first Phase III study for Crohn's disease; (iii) RHB-204, with a planned pivotal Phase III study for
nontuberculous mycobacteria (NTM) infections; (iv) BEKINDA® (RHB-102), with positive
results from a Phase III study for acute gastroenteritis and gastritis and positive results from a Phase II study for IBS-D; (v)
YELIVA® (ABC294640), a first-in-class SK2 selective inhibitor, targeting multiple oncology,
inflammatory and gastrointestinal indications, with an ongoing Phase IIa study for cholangiocarcinoma; (vi)
RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and (vii) RHB-107
(formerly MESUPRON), a Phase II-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory
gastrointestinal diseases.
This press release contains “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking
statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are
beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, (i) the
initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other
therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or
to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the
Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing
of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market
acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully promote Donnatal®,
Mytesi® and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg and commercialize EnteraGam®;
(vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products
approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities;
(viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained
with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s
business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to
establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business
without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual
property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital
requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative
drugs under the Company's Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s
industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual
Report on Form 20-F filed with the SEC on February 22, 2018. All forward-looking statements included in this press release
are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking
statement, whether as a result of new information, future events or otherwise, unless required by law.
Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 adi@redhillbio.com IR contact (U.S.): Timothy McCarthy, CFA, MBA Managing Director, Relationship Manager LifeSci Advisors, LLC +1-212-915-2564 tim@lifesciadvisors.com
